Diabetic Nephropathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Diabetic Nephropathy - Pipeline Review, H2 2016

Diabetic Nephropathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Diabetic Nephropathy - Pipeline Review, H2 2016
Published Aug 10, 2016
220 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Diabetic Nephropathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy
- The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline

  
Source:
Document ID
GMDHC8347IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents210
  List of Tables101
  List of Figures111
Introduction121
  Global Markets Direct Report Coverage121
Diabetic Nephropathy Overview131
Therapeutics Development142
  Pipeline Products for Diabetic Nephropathy Overview141
  Pipeline Products for Diabetic Nephropathy Comparative Analysis151
Diabetic Nephropathy Therapeutics under Development by Companies163
Diabetic Nephropathy Therapeutics under Investigation by Universities/Institutes191
Diabetic Nephropathy Pipeline Products Glance204
  Late Stage Products201
  Clinical Stage Products211
  Early Stage Products221
  Unknown Stage Products231
Diabetic Nephropathy Products under Development by Companies243
Diabetic Nephropathy Products under Investigation by Universities/Institutes271
Diabetic Nephropathy Companies Involved in Therapeutics Development2842
  AbbVie Inc281
  Ampio Pharmaceuticals, Inc.291
  Antisense Therapeutics Limited301
  Araim Pharmaceuticals, Inc.311
  Arena Pharmaceuticals, Inc.321
  Astellas Pharma Inc.331
  AstraZeneca Plc341
  Bayer AG351
  BiOrion Technologies B.V.361
  Boehringer Ingelheim GmbH371
  Cellmid Limited381
  ChemoCentryx, Inc.391
  CSL Limited401
  Daiichi Sankyo Company, Limited411
  Dimerix Bioscience Pty Ltd421
  Dong Wha Pharma Co., Ltd.431
  Dynamis Therapeutics, Inc.441
  Eli Lilly and Company451
  Galectin Therapeutics, Inc.461
  GenKyoTex S.A.471
  Gilead Sciences, Inc.481
  GlaxoSmithKline Plc491
  Glucox Biotech AB501
  GNI Group Ltd.511
  Islet Sciences, Inc.521
  Jenrin Discovery, Inc.531
  Johnson &Johnson541
  Mallinckrodt Plc551
  Mesoblast Limited561
  Mitsubishi Tanabe Pharma Corporation571
  MorphoSys AG581
  Noxxon Pharma AG591
  Omeros Corporation601
  Otsuka Holdings Co., Ltd.611
  PhytoHealth Corporation621
  ProMetic Life Sciences Inc.631
  Serodus ASA641
  Takeda Pharmaceutical Company Limited651
  Theravance Biopharma, Inc.661
  Tobira Therapeutics, Inc.671
  Vascular Pharmaceuticals, Inc.681
  Vicore Pharma AB691
Diabetic Nephropathy Therapeutics Assessment7012
  Assessment by Monotherapy Products701
  Assessment by Target713
  Assessment by Mechanism of Action744
  Assessment by Route of Administration782
  Assessment by Molecule Type802
Drug Profiles82123
  11-RVIVIT Drug Profile821
  A-717 Drug Profile831
  Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology Drug Profile841
  APD-371 Drug Profile851
  APX-115 Drug Profile861
  ASP-8232 Drug Profile871
  ATL-1103 Drug Profile887
  atrasentan hydrochloride Drug Profile952
  baricitinib Drug Profile977
  BI-703704 Drug Profile1041
  BOT-191 Drug Profile1051
  C-21 Drug Profile1062
  canagliflozin Drug Profile1087
  CCX-140 Drug Profile1154
  cenicriviroc mesylate Drug Profile1197
  cibinetide Drug Profile1263
  corticotropin Drug Profile1292
  CS-3150 Drug Profile1312
  CSL-346 Drug Profile1331
  Cyndacel-M Drug Profile1341
  danazol Drug Profile1354
  DMX-250 Drug Profile1391
  DT-23552 Drug Profile1401
  DW-1029M Drug Profile1411
  DYN-12 Drug Profile1422
  emapticap pegol Drug Profile1442
  finerenone Drug Profile1462
  GKT-136901 Drug Profile1481
  GKT-831 Drug Profile1493
  GRMD-02 Drug Profile15210
  GW-610742 Drug Profile1621
  IP-9 Drug Profile1631
  JD-5037 Drug Profile1641
  JNJ-39933673 Drug Profile1651
  MG-132 Drug Profile1661
  Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications Drug Profile1672
  MOR-107 Drug Profile1691
  MPC-300IV Drug Profile1704
  MT-3995 Drug Profile1741
  Nephrilin Drug Profile1751
  Orbcel-M Drug Profile1761
  oxypurinol Drug Profile1771
  PBI-4050 Drug Profile1785
  PBI-4547 Drug Profile1831
  PHN-033 Drug Profile1841
  pirfenidone Drug Profile1851
  probucol Drug Profile1861
  selonsertib Drug Profile1871
  SER-150 Drug Profile1883
  Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy Drug Profile1911
  Small Molecules for Diabetic Nephropathy Drug Profile1921
  Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy Drug Profile1931
  Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Drug Profile1942
  SP-20202 Drug Profile1961
  TAK-272 Drug Profile1971
  TBE-31 Drug Profile1981
  TD-0714 Drug Profile1992
  VPI-2690B Drug Profile2011
  VS-105 Drug Profile2021
  XRX-108 Drug Profile2031
  XRX-221 Drug Profile2041
Diabetic Nephropathy Dormant Projects2053
Diabetic Nephropathy Discontinued Products2081
Diabetic Nephropathy Product Development Milestones20910
  Featured News &Press Releases2091
    Jun 20, 2016: Serodus announces that the first patient is randomized into the second cohort of the SER150 Ph IIa study in Diabetic Nephropathy2091
    Jun 01, 2016: Serodus announces initiation of second cohort in Ph2a study of SER150 in Diabetic Nephropathy2091
    May 13, 2016: Serodus announces positive opinion from Data Safety Monitoring Board on SER150 Ph2a study2091
    Mar 09, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin2101
    Feb 03, 2016: Serodus announces completion of patient enrollment of the first cohort in Phase 2a clinical trial of SER150 in patients with Diabetic Nephropathy2111
    Dec 15, 2015: Lopez McHugh files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury2121
    Dec 09, 2015: SERODUS appoints scientific advisors for development program in diabetic nephropathy (SER150)2121
    Dec 08, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-0714, an Inhibitor of Neprilysin2131
    Nov 05, 2015: ChemoCentryx Highlights CCX140 Phase II Diabetic Nephropathy Trial Results at American Society of Nephrology Annual Meeting2141
    Oct 13, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-0714, an Inhibitor of Neprilysin2141
    Sep 09, 2015: Genkyotex Announces Top-Line Results of Phase 2 Clinical Program2151
    Aug 31, 2015: Bayer Expands Finerenone Clinical Development Programme with Three Phase III Studies in Patients with Chronic Heart Failure and Patients with Diabetic Kidney Disease2161
    Aug 13, 2015: Serodus announces randomization of first patients in Phase IIa clinical trial of SER150 in patients with Diabetic Nephropathy2171
    Aug 10, 2015: ANP Licensing Partner for ATL1103 Cortendo Files Prospectus2171
    Jun 15, 2015: Serodus Receives Approval Of Clinical Trial Application For Ser150 In Diabetic Nephropathy2172
Appendix2192
  Methodology2191
  Coverage2191
  Secondary Research2191
  Primary Research2191
  Expert Panel Validation2191
  Contact Us2191
  Disclaimer2201

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Diabetic Nephropathy - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diabetic-Nephropathy-Pipeline-Review-H2-2016-2088-16355>
  
APA:
Global Markets Direct - Market Research. (2016). Diabetic Nephropathy - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diabetic-Nephropathy-Pipeline-Review-H2-2016-2088-16355>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.